Medical Imaging Specialist Guerbet Celebrates Its 90th Year
By Sanjit Dutt Posted on 15 Nov 2016 |
Guerbet (Paris, France), a specialist in contrast agents and solutions for medical imaging, will be celebrating its 90th year on November 15, 2016. The Group is one of the leading players in medical imaging worldwide and offers a full range of medical solutions and services.
The company is named after the French chemist Marcel Guerbet who discovered the world’s first iodinated contrast agent Lipidol, in 1901. His son André Guerbert, founded the company on November 15, 1926. Following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business, finalized a year ago, Guerbet has grown from being an essentially France-focused company to an international group. Today, 83% of Guerbet’s sales are generated outside France, driven by its four growth engines: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
Guerbet announced the celebration of its 90th anniversary at the French Radiology Congress, which was held in Paris from October 14 to 17, where a fresco featuring the outstanding dates in the company’s history was unveiled in the presence of the President of the French Radiology Society. Over the coming months, Guerbet’s sites worldwide will be organizing events associating their employees and their external audiences in line with its celebration of “90 years of passion.” Guerbet’s website also features a video illustrating 90 years of the company’s history.
Yves L’Epine, Guerbet CEO, said, “Guerbet, which has already been through many turning points, is currently experiencing a key period in its history. It is both particularly exciting and demanding time for our teams. We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging which is innovative and respectful of all its partners.” He added, “More than ever, we are driven to offer indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients.”
Related Links:
Guerbet
The company is named after the French chemist Marcel Guerbet who discovered the world’s first iodinated contrast agent Lipidol, in 1901. His son André Guerbert, founded the company on November 15, 1926. Following the acquisition of Mallinckrodt’s “Contrast Media and Delivery Systems” business, finalized a year ago, Guerbet has grown from being an essentially France-focused company to an international group. Today, 83% of Guerbet’s sales are generated outside France, driven by its four growth engines: contrast agents for MRI, contrast agents for X-ray imaging, Interventional Radiology and Theranostics and Imaging Solutions and Services, including medical devices such as injectors.
Guerbet announced the celebration of its 90th anniversary at the French Radiology Congress, which was held in Paris from October 14 to 17, where a fresco featuring the outstanding dates in the company’s history was unveiled in the presence of the President of the French Radiology Society. Over the coming months, Guerbet’s sites worldwide will be organizing events associating their employees and their external audiences in line with its celebration of “90 years of passion.” Guerbet’s website also features a video illustrating 90 years of the company’s history.
Yves L’Epine, Guerbet CEO, said, “Guerbet, which has already been through many turning points, is currently experiencing a key period in its history. It is both particularly exciting and demanding time for our teams. We are in the process of successfully integrating our major acquisition to build a new global leader in medical imaging which is innovative and respectful of all its partners.” He added, “More than ever, we are driven to offer indispensable solutions for diagnostic and interventional imaging all over the world. Faced with the challenges of aging, the development of chronic diseases and certain cancers that remain difficult to treat, medical imaging opens up an exceptional range of responses which augur well for great progress for patients.”
Related Links:
Guerbet
Latest Industry News News
- Bayer and Google Partner on New AI Product for Radiologists
- Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement
- IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering
- International Societies Suggest Key Considerations for AI Radiology Tools
- Samsung's X-Ray Devices to Be Powered by Lunit AI Solutions for Advanced Chest Screening
- Canon Medical and Olympus Collaborate on Endoscopic Ultrasound Systems
- GE HealthCare Acquires AI Imaging Analysis Company MIM Software
- First Ever International Criteria Lays Foundation for Improved Diagnostic Imaging of Brain Tumors
- RSNA Unveils 10 Most Cited Radiology Studies of 2023
- RSNA 2023 Technical Exhibits to Offer Innovations in AI, 3D Printing and More
- AI Medical Imaging Products to Increase Five-Fold by 2035, Finds Study
- RSNA 2023 Technical Exhibits to Highlight Latest Medical Imaging Innovations
- AI-Powered Technologies to Aid Interpretation of X-Ray and MRI Images for Improved Disease Diagnosis
- Hologic and Bayer Partner to Improve Mammography Imaging
- Global Fixed and Mobile C-Arms Market Driven by Increasing Surgical Procedures
- Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases